Why Sanofi Chose Toronto for Its New Vaccine Plant

Sanofi Boosts Flu Vaccine Capacity in North America

Sanofi has inaugurated a new influenza vaccine facility in Toronto’s North York, a C$925 million build the company describes as the largest biomanufacturing investment in Canada’s history. Named the Charles Best Building, the site will produce Fluzone High-Dose, the company’s influenza vaccine for adults aged 65 and older, and brings roughly 300 highly skilled biomanufacturing jobs with it. Pending regulatory approval, production is expected to start in early 2027 in time for the 2027-28 flu season. For a vaccine market that our research values at $81.9 billion in 2025, the opening is a clear signal: seasonal vaccine capacity is being rebuilt closer to the populations that use it.

Inside the Charles Best Building: What Sanofi Announced

Sanofi confirmed the facility’s inauguration on 16 September 2026, at its 52-acre Toronto campus. The company said the plant is purpose-built for high-dose influenza vaccine production, an area where demand is driven by ageing populations and national immunisation programmes that increasingly recommend enhanced formulations for older adults.

The investment is a genuinely shared one. Sanofi led the C$925 million commitment, with the Government of Canada contributing C$415 million and the Government of Ontario C$55 million. The City of Toronto was named as a partner in the project. James Guy, Canada Country Lead at Sanofi, called the opening a strategic milestone for Sanofi.

That public-private structure matters as much as the headline number. It shows three levels of government and a global manufacturer agreeing that domestic vaccine production capability is worth funding in peacetime, not only during an emergency. The roughly 300 roles the site creates sit in advanced biomanufacturing — process engineering, quality assurance, sterile operations — the skill base a country needs to keep a vaccine plant running year after year.

Why a C$925 Million Plant Matters to an $81.9 Billion Vaccine Market

Our Vaccine Market report puts the global market at $81.9 billion in 2025, up from $65.931 billion in 2021, and projects it reaching $126.379 billion by 2033 at a CAGR of 5.572% over the 2025-2033 window. That is steady, compounding growth built on recurring seasonal demand rather than one-off spikes exactly the kind of demand curve that justifies a multi-decade asset like a dedicated flu vaccine plant.

The Toronto facility strengthens two of the three growth drivers our report identifies. The first is increased government and global health organisation funding  C$470 million of public money in a single project is a textbook example of that driver converting into physical capacity. The second is technological advancement in vaccine development: high-dose formulations for older adults represent exactly the kind of refinement that lifts value per dose rather than simply volume.

It also lands in the segment with the most durable demand profile. Influenza sits among the fourteen disease indications our vaccine research tracks, and the adult end-user segment is where high-dose products concentrate.Our influenza vaccine market research sizes that narrower market at $8,764 million in 2025, growing at 7.41% to $15,526 million by 2033 — faster than the vaccine market overall, which tells you why manufacturers are committing capital to flu specifically.

What Our Report Shows

According to Cognitive Market Research and Consulting’s Vaccine Market report, North America held a 27.75% share of global vaccine revenue in 2025, the second-largest regional position worldwide. The report also identifies the expansion of manufacturing into new geographies as a defining trend of this decade, placing projects like Toronto’s squarely inside a structural shift rather than at its edge.

From Bioreactor Suppliers to Adults Over 65: Who Gains

A plant of this size creates opportunity well beyond the company that built it.

• For vaccine manufacturers, regionally located capacity shortens the distance between production and distribution during a season where timing decides everything. Peers including Seqirus, Merck, Pfizer, Moderna, BioNTech, AstraZeneca and Serum Institute of India ; all tracked as leading participants in our vaccine research operate under the same seasonal clock, and the Toronto model gives the industry a proven template for pairing private capital with public co-investment.

• For equipment and input suppliers, a new sterile biomanufacturing site means sustained orders: bioreactors, filtration and single-use systems, fill-finish lines, cold-chain storage, vials and packaging, plus the calibration and service contracts that follow for the life of the plant.
• For health systems and procurement teams, a domestic source of high-dose influenza vaccine adds a reliable option to seasonal tenders and makes multi-year planning easier.
• For older adults, the outcome is the most direct of all: a dedicated production line for a vaccine formulated specifically for people aged 65 and over, made closer to where it will be administered.

Regional Manufacturing Is Becoming the Industry’s Default Setting

Toronto is one point on a broader line. Our vaccine research names the expansion of manufacturing in emerging and regional markets as a key industry trend, alongside the development of combination and next-generation vaccines. The logic is consistent everywhere: governments want supply security, manufacturers want resilient networks, and both want shorter lead times when a season turns unexpectedly.

Asia Pacific leads global vaccine revenue with a 32.05% share in 2025, followed by North America at 27.75% and Europe at 25.80%. What is notable is that capacity is now being added across all three of these major regions simultaneously — a sign of an industry building redundancy into its network rather than consolidating it.

Early 2027 and the Season That Follows

The near-term milestones are already dated. Regulatory approval of the facility is the next gate, with Sanofi expecting production to begin in early 2027 and the output to serve the 2027-28 flu season. Suppliers bidding for consumables and service contracts will want to be positioned well before commissioning. Procurement teams planning 2027-28 seasonal tenders can begin modelling an additional North American source. And manufacturers weighing their own capacity decisions now have a fully worked public-private template to study.

The Opportunity in Front of the Industry

A C$925 million plant, 300 skilled jobs and three levels of government behind a single vaccine facility is a strong statement of confidence in an industry growing toward $126.379 billion by 2033. For manufacturers and suppliers, the near-term opening is in equipment, inputs and the regional capacity wave this project represents. For health systems and buyers, it is a more secure seasonal supply line.To size these opportunities for your own portfolio, request a sample of our Vaccine Market report or book an analyst consultation with our team.

About this data: figures in this article are drawn from Cognitive Market Research and Consulting’s Vaccine Market report (Report ID CMR660366, data updated August 2026) and our Influenza Vaccine Market report. Analysis is our own.

Related reports from Cognitive Market Research and Consulting

• Vaccine Market Report
• Influenza Vaccine Market Report
• Vaccine Market Research Reports — Pharma & Healthcare